Sanofi Architecture Adjustment Three core businesses were established in China

On May 19th Sanofi announced a major announcement that its china organizational structure would be in line with its global structure, that it would implement the global division's overall responsibility system, restructure its China operations in accordance with the three core global business units of Special Medicines, General Medicines and Vaccines, and appoint a responsible person.Simply put, Sanofi's China business used to be divided into pharmaceuticals and vaccines, Sanofi China and Sanofi Pasteur, and Sanofi Health Pharmaceuticals, which also does health consumer goods.Small partners who regularly follow the push should remember that Sanofi Global announced a new strategic framework late last year, and in support of the new strategy, Sanofi was reorganised into three global divisions: The Global Division of Pharmaceuticals, the Global Division of SpecialTyp, the Global Division of Vaccines, plus an independent consumer health business unit with integrated research and development and production.This time Sanofi China is the adjustment and global structure in agreement, divided into three global divisions of general medicine, special drugs and vaccines in China.Pharmaceutical Global Division ChinaCurrently President of Sanofi China, He Enxuan is the General Manager and President of Sanofi Pharmaceuticals China, and The Global Division of Pharmaceuticals China includes: - Cardiovascular and Mature Products Division, with Liu Wei, former Head of Oncology and CNS, as General Manager;- Primary Health Care Division, continued to serve as General Manager by ShengXuanzhou,- Diabetes Division, continued to be General Manager by Nolin, and- Business and Retail Division, continued to be served as General Manager by Xia Chun.Special Pharmaceuticals Global Division ChinaSanofi Pharmaceuticals Global Division China General Manager continues to be the current General Manager of Special Pharmaceuticals Division Wang Baikang, who this year from Novarco Pharmaceuticals, joined Sanofi before taking charge of Novarma Pharmaceutical ophthalmology business.Special Pharmaceuticals China business and operations team also made the appointment, Dabito business by Qiu Fengxuan continued to be in charge, rare diseases and rare blood diseases business continued to be responsible for Zhai Lei, and appointed the current Sanofi China President Special Assistant Lu Shixuan as the head of the neuroscience business.The head of the new product planning and business innovation team also continues to be responsible for Fu Shiqing, Lai Xueqing and Ding Yujie respectively, and the head of the excellent planning team is still in the process of being determined.Vaccine Global Division ChinaCurrently Sanofi Pasteur China General Manager Zhang Ping continues to serve as General Manager of Vaccine Global Division China, the subordinate leadership team positions remain unchanged, such as sales general manager continues to be served by Feng Kochang, chief marketing officer continues to be served by Cao Shaohua, business head Li Zhenlei new product planning head Wang Jianxiong and so on.These are the new organizational structure and leadership teams in Sanofi China.On December 9th Paul Hudson, Sanofi's chief executive, announced a "full victory" for the new strategic framework, saying it would lead Sanofi into the next cycle with the creation of three global divisions for general medicines, specialty drugs and vaccines, as well as an independent consumer health business unit.According to Dami understand that after the Spring Festival, Sanofi China has completed the leadership level of planning and deployment, and today's official internal notice to complete the adjustment and appointment.The formal determination of Sanofi's new global strategy for China is good news for Sanofi's small partners in China, many of which have various guesses about the future organizational structure because of the volume of their products. (Pharmaceutical representative)